TD-HS856066

Research Grade Perakizumab(TD-HS856066) is ahumanized monoclonalantibody detectingCTLA-8inELISA, Bioactivity: FACS, Functional assay, Research in vivo. Suitable forHuman.HighlightsMulti-Application— Validated across multiple applications.

Human

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Humanized

IgG1-kappa

Human

Monoclonal

CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, IL17, IL-17A, IL17A, CTLA8, IL-17, Interleukin-17A

Please contact with the lab for this information.

>95% as determined by SDS-PAGE.

Protein A/G purified from cell culture supernatant.

Q16552

Liquid

0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

RG4934, RO5310074, 1331830-76-2

Ixekizumab is a humanized monoclonal antibody to interleukin-17A which acts as an antiinflammatory agent and is used to treat moderate-to-severe plaque psoriasis. Ixekizumab has not been linked to serum enzyme elevations during therapy or to instances of idiosyncratic acute liver injury.• The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond., PMID:30127781• Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability., PMID:26431948• IL-17A functions and the therapeutic use of IL-17A and IL-17RA targeted antibodies for cancer treatment., PMID:37579542• The role of IL-17 and anti-IL-17 agents in the immunopathogenesis and management of autoimmune and inflammatory diseases., PMID:34863654• IL-17 for therapy., PMID:28633806• Association Between., PMID:35271496• Vunakizumab: First Approval., PMID:39497021• The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies., PMID:31278139• IL-17A Modulates Peritoneal Macrophage Recruitment and M2 Polarization in Endometriosis., PMID:32117261• Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F., PMID:32973785

SDS-PAGE for Research Grade Perakizumab

For research use only. Not suitable for clinical or therapeutic use.